Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP585299.RAvxD5vLCmvoDYhs9F3cHWKkJaKiGOhUgrvstF0S2p2eQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP585299.RAvxD5vLCmvoDYhs9F3cHWKkJaKiGOhUgrvstF0S2p2eQ130_assertion type Assertion NP585299.RAvxD5vLCmvoDYhs9F3cHWKkJaKiGOhUgrvstF0S2p2eQ130_head.
- NP585299.RAvxD5vLCmvoDYhs9F3cHWKkJaKiGOhUgrvstF0S2p2eQ130_assertion description "[FOXP2 (>10% nuclear positivity) was detectable in 90.2% of MM (55/61) and 90.9% of MGUS (10/11) patients, showing more frequent expression than CD56 and labelling 75% of CD56-negative MM (9/12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP585299.RAvxD5vLCmvoDYhs9F3cHWKkJaKiGOhUgrvstF0S2p2eQ130_provenance.
- NP585299.RAvxD5vLCmvoDYhs9F3cHWKkJaKiGOhUgrvstF0S2p2eQ130_assertion evidence source_evidence_literature NP585299.RAvxD5vLCmvoDYhs9F3cHWKkJaKiGOhUgrvstF0S2p2eQ130_provenance.
- NP585299.RAvxD5vLCmvoDYhs9F3cHWKkJaKiGOhUgrvstF0S2p2eQ130_assertion SIO_000772 20096010 NP585299.RAvxD5vLCmvoDYhs9F3cHWKkJaKiGOhUgrvstF0S2p2eQ130_provenance.
- NP585299.RAvxD5vLCmvoDYhs9F3cHWKkJaKiGOhUgrvstF0S2p2eQ130_assertion wasDerivedFrom befree-20150227 NP585299.RAvxD5vLCmvoDYhs9F3cHWKkJaKiGOhUgrvstF0S2p2eQ130_provenance.
- NP585299.RAvxD5vLCmvoDYhs9F3cHWKkJaKiGOhUgrvstF0S2p2eQ130_assertion wasGeneratedBy ECO_0000203 NP585299.RAvxD5vLCmvoDYhs9F3cHWKkJaKiGOhUgrvstF0S2p2eQ130_provenance.